|
Variable
|
n (%) or mean ± SD
|
|---|
|
Sex, males
|
112 (76.2)
|
|
Age, years
|
65.4 (10.6)
|
|
BMI, kg/m2
|
26.4 (4.1)
|
|
(Previous) smoker
|
68 (46.3)
|
|
Hypertension
|
79 (53.7)
|
|
Diabetes mellitus
|
16 (10.9)
|
|
Nephrostomy catheter
|
14 (10.1)
|
|
ASA class
|
|
ASA class 1
|
20 (13.6)
|
|
ASA class 2
|
91 (61.9)
|
|
ASA class 3
|
36 (24.5)
|
|
Indication
|
|
Bladder cancer
|
123 (81.6)
|
|
Stage T ≥ T2
|
73 (59.3)
|
|
Other malignancy
|
13 (8.8)
|
|
Functional
|
8 (5.4)
|
|
Other
|
3 (2.0)
|
|
Colonization with MDRO
|
7 (4.8)
|
|
Guideline-accordant prophylaxis
|
116 (78.9)
|
|
Correct choice
|
134 (91.2)
|
|
Correct dose
|
124 (92.5)
|
|
Administration < 60 min prior to incision
|
142 (91.2)
|
|
Type of diversion
|
|
Ileal conduit
|
120 (81.6)
|
|
Hautmann neobladder
|
27 (18.4)
|
|
Duration surgery, minutes
|
216 (75)
|
|
Blood loss, ml
|
1031 (700)
|
- Abbreviations: ASA American Society of Anesthesiologists, BMI body mass index, IQR interquartile range, MDRO multidrug resistant microorganism, SD standard deviation
